Skip to content

Denali Therapeutics Inc. DNLI Preferred Stock Par Value Per Share

Preferred Stock Par Value Per Share at other companies

ALN
Alnylam PharmaceuticalsALNY
$0.010.0%
BioCryst Pharmaceuticals logo
BioCryst PharmaceuticalsBCRX
$0.010.0%
Biogen logo
BiogenBIIB
BridgeBio Pharma logo
BridgeBio PharmaBBIO
Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX
Praxis Precision Medicines, Inc. logo
Praxis Precision Medicines, Inc.PRAX

Other financials

Income statement

See full
Revenue-
Operating income-$137.4M+5.6%
Net income-$128.4M+3.4%
EPS (diluted)-$0.69+11.5%

Balance sheet

See full
Cash & equivalents$390.7M+551%
Total debt$40.0M-22.3%
Total equity$926.1M-17.5%
Total assets$1.3B-0.4%

Cash flow

See full
Operating cash flow-$131.2M+0.2%
CapEx$2.5M-51.4%
Free cash flow-$133.7M+2.1%

Valuation

See full
Market cap$3.93B+54.2%

Profitability

See full
Operating margin-37,938%-37,986pp
Net margin-33,121.9%-33,159pp
FCF margin-31,736.3%-31,830pp

Returns & leverage

See full
Return on equity-49.6%+34.2pp
Debt / equity0.0×
Current ratio9.3×-0.3×

Where this comes from

Reported directly by Denali Therapeutics Inc. in its filing.

Tagged under the XBRL concept us-gaap:PreferredStockParOrStatedValuePerShare.

The official record: Denali Therapeutics Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Denali Therapeutics Inc.'s preferred stock par value per share.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Denali Therapeutics Inc.'s preferred stock par value per share?
Denali Therapeutics Inc. (DNLI) reported preferred stock par value per share of $0.01 in Q1 2026.
How has Denali Therapeutics Inc.'s preferred stock par value per share changed year-over-year?
Denali Therapeutics Inc.'s preferred stock par value per share decreased by 0.0% year-over-year, from $0.01 to $0.01.
What is the long-term trend for Denali Therapeutics Inc.'s preferred stock par value per share?
Over 5 years (2020 to 2025), Denali Therapeutics Inc.'s preferred stock par value per share has grown at a 0.0% compound annual growth rate (CAGR), from $0.01 to $0.01.
What does preferred stock par value per share mean?
The par value per share of preferred stock is a nominal value assigned to preferred shares for accounting and legal purposes. It does not reflect the market value or the liquidation preference of the stock. It is primarily a regulatory and historical accounting figure.